Foghorn Therapeutics Inc. (FHTX): Nasdaq/NYSE listing notice — Foghorn Therapeutics receives Nasdaq non-compliance notice over audit committee composition

Foghorn Therapeutics Inc.

Nasdaq notified Foghorn on Jan 23, 2025 that its audit committee has only two members, violating Listing Rule 5605.
Vacancy follows resignation of director Adam M. Koppel from board and audit committee effective Dec 29, 2024.
Cure period runs until earlier of next annual meeting or Dec 29, 2025; if meeting before June 27, 2025, then by June 27, 2025.
Board intends to appoint a new independent director to fill the audit committee vacancy within the cure period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605, 5605(c)(4)

Exact text from the filing

January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee requirements as set forth in Nasdaq Listing Rule 5605. Nasdaq Listing Rule 5605 requires, among other things, that each listed company must have an audit committee comprised of at least three members, each of whom must meet certain independence and other qualifications as set forth in such rule. As a result of the previously reported resignation of Adam M. Koppel, M.D., Ph.D. f

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee.

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee

Exact text from the filing

January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee

View on SEC.gov

Browse all listing & compliance notices →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-002466

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.